TACTI-002 2nd line lung cancer data presented at 2022 WCLC
Filed with ASX · · 4 pages · English
Earlier from Immutep
- Quarterly Activities/Appendix 4C Cash Flow Report
- Immutep granted Japanese Patent for IMP761
- Webcast slides for 1st line NSCLC data from TACTI-002 trial
- Immutep announces publication of ASCO 2022 abstracts
- New & significant data from AIPAC phase 2b trial in MBC
Later from Immutep
- Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1
- Appendix 4E & 2022 Full Year Statutory Accounts
- New investigator-initiated ph2 trial in Soft Tissue Sarcoma
- Clinical Development Update for Eftilagimod Alpha
- Immutep Receives A$2.7 million R&D French Tax Incentive
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep